Article Figures & Data
Figures
- Fig. 1.
Kaplan-Meier estimate of survival among all 95 patients in the study.
- Fig. 2.
Time of radiographic progression-free survival plotted against the time to death, among patients for whom both radiographic progression and death were recorded.
- Fig. 3.
Time of PSA progression-free survival plotted against the time to death, among patients for whom both PSA progression and death were recorded.
- Fig. 4.
Association between radiographic progression-free survival and survival as a function of the time of the progression-free survival event (radiographic progression, death, or censoring). Solid line, local Kendall's τ estimates; dotted lines, the corresponding 95% pointwise confidence intervals.
- Fig. 5.
Association between PSA progression-free survival and survival as a function of the time of the progression-free survival event. Solid line, local Kendall's τ estimates; dotted lines, the corresponding 95% pointwise confidence intervals.
Tables
- Table 1.
Distribution of disease in patients with castrate-metastatic prostate cancer
Category Overall Memorial Sloan-Kettering Cancer Center Total no. of patients reviewed 171 116 TEC (1997-1999) 49 40 Hi-TEC (1999-2000) 30 24 Epothilone (2001-2003) 98 52 Median PSA at baseline (all studies) 97.9 (range, 0.52-2,282.2) 91.4 (range, 0.52-2,282.15) Number of patients with bone only 51 (29.8%) 35 (30.2%) bone and soft tissue 95 (55.6%) 63 (54.3%) soft tissue only 25 (14.6%) 18 (15.5%) *Thirty-nine percent to 40% had “measurable disease” (including visceral disease).
Volume 13, Issue 5
